Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.

Sauvé M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, Drucker DJ.

Diabetes. 2010 Apr;59(4):1063-73. doi: 10.2337/db09-0955. Epub 2010 Jan 22.

2.

Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.

McCormick LM, Kydd AC, Read PA, Ring LS, Bond SJ, Hoole SP, Dutka DP.

Circ Cardiovasc Imaging. 2014 Mar;7(2):274-81. doi: 10.1161/CIRCIMAGING.113.000785. Epub 2014 Feb 6.

3.

Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α.

Connelly KA, Advani A, Zhang Y, Advani SL, Kabir G, Abadeh A, Desjardins JF, Mitchell M, Thai K, Gilbert RE.

J Diabetes. 2016 Jan;8(1):63-75. doi: 10.1111/1753-0407.12258. Epub 2015 Mar 4.

PMID:
25565455
4.

DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes.

Connelly KA, Zhang Y, Advani A, Advani SL, Thai K, Yuen DA, Gilbert RE.

Cardiovasc Ther. 2013 Oct;31(5):259-67. doi: 10.1111/1755-5922.12005.

PMID:
22963483
5.

Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.

Inthachai T, Lekawanvijit S, Kumfu S, Apaijai N, Pongkan W, Chattipakorn SC, Chattipakorn N.

Exp Physiol. 2015 Jun;100(6):667-79. doi: 10.1113/EP085108. Epub 2015 May 13.

6.

DPP4 Inhibition Ameliorates Cardiac Function by Blocking the Cleavage of HMGB1 in Diabetic Mice After Myocardial Infarction.

Sato A, Suzuki S, Watanabe S, Shimizu T, Nakamura Y, Misaka T, Yokokawa T, Shishido T, Saitoh SI, Ishida T, Kubota I, Takeishi Y.

Int Heart J. 2017 Oct 21;58(5):778-786. doi: 10.1536/ihj.16-547. Epub 2017 Sep 30.

7.

Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice.

Mulvihill EE, Varin EM, Ussher JR, Campbell JE, Bang KW, Abdullah T, Baggio LL, Drucker DJ.

Diabetes. 2016 Mar;65(3):742-54. doi: 10.2337/db15-1224. Epub 2015 Dec 15.

8.

Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.

Hausenloy DJ, Whittington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N, Mocanu MM, Yellon DM.

Cardiovasc Diabetol. 2013 Oct 22;12:154. doi: 10.1186/1475-2840-12-154.

9.

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.

Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP.

Circ Cardiovasc Imaging. 2010 Mar;3(2):195-201. doi: 10.1161/CIRCIMAGING.109.899377. Epub 2010 Jan 14.

10.

All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.

Scheller NM, Mogensen UM, Andersson C, Vaag A, Torp-Pedersen C.

Diabetes Obes Metab. 2014 Mar;16(3):231-6. doi: 10.1111/dom.12197. Epub 2013 Sep 10.

PMID:
24020750
11.

DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion.

Ku HC, Chen WP, Su MJ.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Aug;384(2):197-207. doi: 10.1007/s00210-011-0665-3. Epub 2011 Jul 12.

PMID:
21748358
12.

Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.

Kim SJ, Nian C, Doudet DJ, McIntosh CH.

Diabetes. 2008 May;57(5):1331-9. doi: 10.2337/db07-1639. Epub 2008 Feb 25.

13.

DPP-4 inhibition has beneficial effects on the heart after myocardial infarction.

Kubota A, Takano H, Wang H, Hasegawa H, Tadokoro H, Hirose M, Kobara Y, Yamada-Inagawa T, Komuro I, Kobayashi Y.

J Mol Cell Cardiol. 2016 Feb;91:72-80. doi: 10.1016/j.yjmcc.2015.12.026. Epub 2015 Dec 29.

PMID:
26739213
14.

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.

Mu J, Petrov A, Eiermann GJ, Woods J, Zhou YP, Li Z, Zycband E, Feng Y, Zhu L, Roy RS, Howard AD, Li C, Thornberry NA, Zhang BB.

Eur J Pharmacol. 2009 Nov 25;623(1-3):148-54. doi: 10.1016/j.ejphar.2009.09.027. Epub 2009 Sep 16.

PMID:
19765579
15.

Inhibition of dipeptidyl peptidase-IV enzyme activity protects against myocardial ischemia-reperfusion injury in rats.

Chua S, Lee FY, Tsai TH, Sheu JJ, Leu S, Sun CK, Chen YL, Chang HW, Chai HT, Liu CF, Lu HI, Yip HK.

J Transl Med. 2014 Dec 13;12:357. doi: 10.1186/s12967-014-0357-0.

16.

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.

Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group.

Lancet. 2010 Apr 24;375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8. Erratum in: Lancet. 2010 Jul 24;376(9737):234.

PMID:
20417856
17.

Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.

Jackson EK, Mi Z, Tofovic SP, Gillespie DG.

Hypertension. 2015 Jan;65(1):238-49. doi: 10.1161/HYPERTENSIONAHA.114.04631. Epub 2014 Nov 3. Erratum in: Hypertension. 2015 Apr;65(4):e17.

18.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.

Scheen AJ.

Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Review.

19.

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.

Yin M, Silljé HH, Meissner M, van Gilst WH, de Boer RA.

Cardiovasc Diabetol. 2011 Sep 28;10:85. doi: 10.1186/1475-2840-10-85.

20.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.

Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.

PMID:
17593236

Supplemental Content

Support Center